Emily Parker @911GlobalMeds
Evolving role of zoledronic acid in early breast cancer

Most women diagnosed in the early stages of breast cancer are likely to have a great prognosis. It is also likely that they remain disease free for several years after their treatment ends.

However, the side effects of such treatments associated with bone issues are also likely to have effect the patient's bone health in the long run.

The bone loss associated with breast cancer therapy like endocrine therapy may contribute towards the risk of osteoporosis and bone fractures in the long run.

Several guidelines for treatment are now changed to include the need for preserving bone health in adjuvant therapy regimes and any measures involved.

Source: https://shorturl.at/gnZ68

02:35 AM - Mar 08, 2024
Only people mentioned by 911GlobalMeds in this post can reply

No replys yet!

It seems that this publication does not yet have any comments. In order to respond to this publication from Emily Parker, click on at the bottom under it